Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that ...

Notes from a recent meeting of the CDC’s Advisory Committee on Immunization Practices’ COVID-19 Work Group show health ...

As the 2020 pandemic became a distant memory and millions of Americans returned back to their old lives, some were left ...

In the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) was a top performer, from both a share-price and an ...

The far-right government of Giorgia Meloni wants to rehabilitate this movement, which celebrated speed, power, industrial ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...

The most recent trading session ended with Moderna (MRNA) standing at $24.73, reflecting a -1.85% shift from the previouse trading day's closing. The stock's performance was behind the S&P 500's daily ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

Furthering its goal to grow the reach of its mRNA vaccines and guard against future pandemics, Moderna cleared a key ...

The committee endorsed lowering the age at which some people can receive RSV vaccines, but stopped short of recommending ...

Leerink Partners analyst David Risinger maintained a Sell rating on Moderna (MRNA – Research Report) yesterday and set a price target of ...

Guidelines from the Advisory Committee on Immunization Practices help physicians decide what vaccines to recommend to patients and are also used for determining insurance coverage in the U.S. The ...